



Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer

CAMBRIDGE, Mass. – October 26, 2022 – [Nimbus Therapeutics](#), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the appointment of Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer.

“I am delighted to welcome Nathalie to our leadership team as Nimbus advances multiple potential breakthrough candidates into their next phase of development, including our clinical TYK2 and HPK1 inhibitors,” said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. “Nathalie’s strategic leadership and extensive clinical experience will be an asset to our growing clinical development team, and her wide range of experience in the development and commercialization of both small and large molecules in various therapeutic areas is an ideal fit for the breadth of Nimbus’ pipeline.”

Dr. Franchimont joins Nimbus from Biogen, where she served as Senior Vice President, Head of Multiple Sclerosis and Immunology Development Unit. She previously held a variety of other leadership roles at Biogen, including leading the Multiple Sclerosis Research and Early Development Unit, the New Indications Research and Early Development Unit and the Immunology Drug Innovation Unit. Prior to joining Biogen, Dr. Franchimont held Medical Affairs and Clinical Development roles at Amgen. A rheumatologist by background, Dr. Franchimont trained at the University of Liège and has held research fellow and research associate roles at the University of Connecticut School of Medicine, Yale University School of Medicine and University of Liège. Dr. Franchimont has served on the Board of Directors of OMass Therapeutics since 2020.

“I am incredibly pleased to join Nimbus at a very exciting time in the company’s history and work with this accomplished team to bring new treatment possibilities to patients,” said Dr. Franchimont. “Nimbus has advanced compelling medicines targeting TYK2 and HPK1 to the clinic and is developing strategies to address multiple other highly sought-after targets. NDI-034858, in ongoing Phase 2b trials, is a great example of the power of Nimbus’ approach and I believe it has potential to be a differentiated, best-in-class oral allosteric TYK2 inhibitor for the treatment of psoriasis, psoriatic arthritis and other immune-mediated diseases.”

About Nimbus Therapeutics

Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. Nimbus combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus has designed, discovered and developed a diverse portfolio of clinical and preclinical programs focused on inflammatory and autoimmune disorders, cancer and metabolic diseases, including three internally discovered compounds that have advanced into clinical trials. Nimbus is headquartered in Cambridge, MA. To learn more about Nimbus, please visit www.nimbustx.com.

Media Contact

Chris Railey, (617) 834-0936
Ten Bridge Communications
chris@tenbridgecommunications.com